Clicky

Pacira Pharmaceuticals, Inc.(PCRX)

Description: Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, commercializes, and manufactures pharmaceutical products for use in hospitals and ambulatory surgery centers worldwide. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. The company markets EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic, indicated for administration into the surgical site to produce postsurgical analgesia; and DepoCyt(e), a liposomal formulation of the chemotherapeutic agent cytarabine indicated for the intrathecal treatment of lymphomatous meningitis, a cancer of the immune system. Its product pipeline comprise EXPAREL that has completed Phase II clinical trials for postsurgical analgesia-nerve block administration; DepoNSAID, which is in preclinical trials for the relief of acute pain; and DepoMethotrexate that is in preclinical trials for the treatment of rheumatoid arthritis and oncology, as well as Bupivacaine Liposome Injectable Suspension for veterinary postsurgical analgesia. Pacira Pharmaceuticals, Inc. has a development and commercialization agreement, and related supply agreement with Aratana Therapeutics, Inc. The company was formerly known as Pacira, Inc. and changed its name to Pacira Pharmaceuticals, Inc. in October 2010. Pacira Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.


Keywords: Medicine Pharmaceutical Cancer Pharmaceutical Products Pain Surgery Pharmacology Immune System Rheumatoid Arthritis Lymphoma Drug Delivery Suspension Nerve Acute Pain Meningitis Piperidines Drug Delivery Technology Methotrexate Bupivacaine Liposome Local Anesthetics Acetanilides Local Anesthetic Surgical Site Treatment Of Lymphoma Intrathecal Administration

Home Page: www.pacira.com

PCRX Technical Analysis

5401 West Kennedy Boulevard
Tampa, FL 33609
United States
Phone: 813 553 6680


Officers

Name Title
Mr. David M. Stack Chairman & CEO
Mr. Charles A. Reinhart III, CPA, M.B.A. Chief Financial Officer
Dr. Roy Winston M.D. Chief Medical Officer
Mr. Max Reinhardt Pres of Rest of World
Dr. Jonathan Slonin M.D. Chief Clinical Officer
Mr. Daryl Gaugler Chief Operating Officer
Ms. Lauren Bullaro Riker Principal Accounting Officer & VP of Fin.
Mr. Charles Laranjeira Chief Technical Officer
Ms. Kristen Williams J.D. Chief Admin. Officer & Sec.
Susan Mesco Head of Investor Relations

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 10.6496
Trailing PE: 83.0444
Price-to-Book MRQ: 2.7316
Price-to-Sales TTM: 2.9407
IPO Date: 2011-02-03
Fiscal Year End: December
Full Time Employees: 697
Back to stocks